-
Development of an automated, high-throughput SARS-CoV-2 neutralization assay based on a pseudotyped virus using a vesicular stomatitis virus (VSV) vector
Liang Z, Wu X, Wu J, Liu S, Tong J, Li T, Yu Y, Zhang L, Zhao C, Lu Q, Qin H, Nie J, Huang W, Wang Y. Development of an automated, high-throughput SARS-CoV-2 neutralization assay based on a pseudotyped virus using a vesicular stomatitis virus (VSV) vector. Emerg Microbes Infect. 2023 Dec;12(2):e2261566. doi: 10.1080/22221751.2023.2261566. Epub 2023 Sep 28. PMID: 37727107; PMCID: PMC10540657. -
Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.86
Yang S, Yu Y, Jian F, Song W, Yisimayi A, Chen X, Xu Y, Wang P, Wang J, Yu L, Niu X, Wang J, Xiao T, An R, Wang Y, Gu Q, Shao F, Jin R, Shen Z, Wang Y, Cao Y. Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.86. Lancet Infect Dis. 2023 Nov;23(11):e457-e459. doi: 10.1016/S1473-3099(23)00573-X. Epub 2023 Sep 19. PMID: 37738994. -
SARS-CoV-2 spike-specific T(FH) cells exhibit unique responses in infected and vaccinated individuals
He R, Zheng X, Zhang J, Liu B, Wang Q, Wu Q, Liu Z, Chang F, Hu Y, Xie T, Liu Y, Chen J, Yang J, Teng S, Lu R, Pan D, Wang Y, Peng L, Huang W, Terzieva V, Liu W, Wang Y, Li YP, Qu X. SARS-CoV-2 spike-specific TFH cells exhibit unique responses in infected and vaccinated individuals. Signal Transduct Target Ther. 2023 Oct 6;8(1):393. doi: 10.1038/s41392-023-01650-x. PMID: 37802996; PMCID: PMC10558553. -
Analysis of SARS-CoV-2 variants B.1.617: host tropism, proteolytic activation, cell-cell fusion, and neutralization sensitivity
Zhang L, Li Q, Wu J, Yu Y, Zhang Y, Nie J, Liang Z, Cui Z, Liu S, Wang H, Ding R, Jiang F, Li T, Nie L, Lu Q, Li J, Qin L, Jiang Y, Shi Y, Xu W, Huang W, Wang Y. Analysis of SARS-CoV-2 variants B.1.617: host tropism, proteolytic activation, cell-cell fusion, and neutralization sensitivity. Emerg Microbes Infect. 2022 Dec;11(1):1024-1036. doi: 10.1080/22221751.2022.2054369. PMID: 35293847; PMCID: PMC9004538. -
A second functional furin site in the SARS-CoV-2 spike protein
Zhang Y, Zhang L, Wu J, Yu Y, Liu S, Li T, Li Q, Ding R, Wang H, Nie J, Cui Z, Wang Y, Huang W, Wang Y. A second functional furin site in the SARS-CoV-2 spike protein. Emerg Microbes Infect. 2022 Dec;11(1):182-194. doi: 10.1080/22221751.2021.2014284. PMID: 34856891; PMCID: PMC8741242. -
The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron
Zhang L, Li Q, Liang Z, Li T, Liu S, Cui Q, Nie J, Wu Q, Qu X, Huang W, Wang Y. The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron. Emerg Microbes Infect. 2022 Dec;11(1):1-5. doi: 10.1080/22221751.2021.2017757. PMID: 34890524; PMCID: PMC8725892. -
ACE2 decoy receptor generated by high-throughput saturation mutagenesis efficiently neutralizes SARS-CoV-2 and its prevalent variants
Wang B, Zhao J, Liu S, Feng J, Luo Y, He X, Wang Y, Ge F, Wang J, Ye B, Huang W, Bo X, Wang Y, Xi JJ. ACE2 decoy receptor generated by high-throughput saturation mutagenesis efficiently neutralizes SARS-CoV-2 and its prevalent variants. Emerg Microbes Infect. 2022 Dec;11(1):1488-1499. doi: 10.1080/22221751.2022.2079426. PMID: 35587428; PMCID: PMC9176695. -
Analysis of the evolution, infectivity and antigenicity of circulating rabies virus strains
Cai M, Liu H, Jiang F, Sun Y, Wang W, An Y, Zhang M, Li X, Liu D, Li Y, Yu Y, Huang W, Wang Y. Analysis of the evolution, infectivity and antigenicity of circulating rabies virus strains. Emerg Microbes Infect. 2022 Dec;11(1):1474-1487. doi: 10.1080/22221751.2022.2078742. PMID: 35570580; PMCID: PMC9176641. -
Retrospective immunogenicity analysis of seasonal flu H3N2 vaccines recommended in the past ten years using immunized animal sera
Zhang M, An Y, Wu X, Cai M, Zhang X, Yang C, Tong J, Cui Z, Li X, Huang W, Zhao C, Wang Y. Retrospective immunogenicity analysis of seasonal flu H3N2 vaccines recommended in the past ten years using immunized animal sera. EBioMedicine. 2022 Dec;86:104350. doi: 10.1016/j.ebiom.2022.104350. Epub 2022 Nov 17. PMID: 36403423; PMCID: PMC9678686. -
Analysis of cross neutralizing activity of antibodies from sera of severe fever with thrombocytopenia syndrome patients to deal with different genotype strains
Xu J, Liu Y, Zhang F, Wang X, Huang W, Wu Y, Li B, Zhuang J, Bing Y, Wang Y, Qiao Y. Analysis of cross neutralizing activity of antibodies from sera of severe fever with thrombocytopenia syndrome patients to deal with different genotype strains. Front Microbiol. 2022 Oct 20;13:1020545. doi: 10.3389/fmicb.2022.1020545. PMID: 36338043; PMCID: PMC9631478.